A Phase 1 interventional study of It is loaded with a mesenchymal stem cells reaction device for blood purification in Liver Failure, sponsored by Kebo Zhong. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Kebo Zhong · Phase 1, Interventional, and Treatment
The goal of this clinical trial is to learn if mesenchymal stem cells in blood purification works to treat liver failure in adults. It will also learn about the safety and effectiveness of mesenchymal stem cells in blood purification. The main questions it aims to answer are:1.Does mesenchymal stem cells in blood purification improve the condition of patients with liver failure? 2.What medical problems do participants have when taking mesenchymal stem cells in blood purification? Participants will receive routine medical treatment and blood purification treatment with mesenchymal stem cells.These cells work outside the body and do not enter the body. We will: 1.Collect samples from participants such as blood, Urine and feces. 2.record post-treatment outcomes such as survival rate at 4 weeks after treatment, conversion rate to liver transplantation, Inflammatory, survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment, and liver disease indicators(prothrombin time activity percentage, lactic aicd, blood ammonia, α-fetoprotein, ferritin).
190 studies on the registry are indexed under Liver Failure; 33 are open to participants now.
This study's planned enrollment of 10 is below the median of 57 across 113 interventional studies indexed under Liver Failure.
Browse Liver Failure studies →This is the only study on the registry with Kebo Zhong as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: It is loaded with a mesenchymal stem cells reaction device for blood purification
Artificial liver blood purification therapy is performed using a mesenchymal stem cells reactor.
Survival rate on day 28 after treatment
researchers record all participators' survival condition from enrollment to day 28 after treatment.
Time frame: From enrollment to day 28 after treatment.
conversion rate to liver transplantation
researchers record participators' condition of conversion to liver transplantation from enrollment to day 28, 56, 84 after treatment.
Time frame: From enrollment to day 28, 56, 84 after treatment.
Interleukin-6(IL-6)
Participators accept blood tests of a Inflammatory factor: reflect systemic inflammatory status.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Survival rate on day 7, 14, 56, 84 after treatment
Researchers record participators' survival condition from enrollment to day 7, 14, 56, 84 after treatment.
Time frame: From enrollment to day 7, 14, 56, 84 after treatment.
lactic aicd
Participators accept blood tests of liver disease indicators lactic aicd from enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Model for End-Stage Liver Disease score
The internationally recognized prognostic scoring system for end-stage liver disease is used to determine prioritization for liver transplantation and predict patient survival rates.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score
To assess short-term mortality rates (28-day/90-day) in patients with acute-on-chronic liver failure (ACLF) and guide prioritization for liver transplantation and intensive care resource allocation.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
tumor necrosis factor α (TNF-α)
Participators accept blood tests of a Inflammatory factor: reflect systemic inflammatory status.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
C-reactive protein (CRP)
Participators accept blood tests of a Inflammatory factor: reflect systemic inflammatory status.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
blood ammonia
Participators accept blood tests of liver disease indicators blood ammonia from enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Alpha-fetoprotein (AFP)
Participators accept blood tests of liver disease indicators AFP from enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
ferritin
Participators accept blood tests of liver disease indicators ferritin from enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Time frame: From enrollment to day 1, 3, 5, 7, 14, 28, 56, 84 after treatment.
Incidence rate of adverse events (AE incidence rate)
Record treatment-related adverse reactions occurring during the intervention.
Time frame: Throughout the entire course of MSC-based blood purification therapy.
Plan to share: No — We fully acknowledge the significance of data sharing. However, owing to the policies and confidentiality agreements adhered to in our laboratory, we regretfully cannot furnish the raw data. Nevertheless, we have meticulously presented a comprehensive account of the experimental design, analysis, results, and the procedures employed for data analysis and processing.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.